Compared with TP53 wild type, patients with TP53 mutations were younger (P = 0.01; median, 71 vs 77 years); AML with TP53 mutation tended to more often develop from antecedent MDS (P = 0.12) (Table 3). This evidence concerns the gene TP53 and acute myeloid leukemia.